Tan Tock Seng Hospital | Clinical Research and Innovation Office

Research site
16 Jalan Tan Tock Seng, Singapore, Central Singapore, Singapore
Site insights

Top conditions

Stroke (13 trials)

Non-Small-Cell Lung Carcinoma (10 trials)

Coronary Artery Disease (9 trials)

Carcinoma (8 trials)

Lung Cancer (8 trials)

Top treatments

Tenofovir Disoproxil Fumarate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


36 of 188
Status: Active
Trial type: Interventional
Funder type: Industry

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus...

Active, not recruiting
Psoriatic Arthritis
Drug: Adalimumab
Drug: Placebo to Adalimumab

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (d...

Pulmonary Arterial Hypertension
Drug: Placebo
Drug: AV-101

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab an...

Carcinoma, Hepatocellular
Drug: Relatlimab
Drug: Bevacizumab

The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combinat...

Active, not recruiting
Breast Neoplasms
Drug: Letrozole
Drug: Placebo

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearr...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Pemetrexed

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response aft...

Lupus Nephritis
Drug: placebo
Drug: zetomipzomib

The purpose of this study is to will evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemothe...

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Drug: TAS6417

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Diffuse Large B-cell Lymphoma (DLBCL)
Drug: Doxorubicin
Drug: Prednisone/Prednisolone

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: Placebo
Drug: BI 1015550

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given i...

Non Small Cell Lung Cancer
Drug: Zirabev
Drug: Amivantamab

To assess:efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification,...

Glioblastoma Multiforme
Brain Tumor
Drug: APL-101 Oral Capsules

BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study.A total of 1'948 subjects will be randomized...

Active, not recruiting
Coronary Artery Disease
Device: Percutaneous coronary intervention

Trial sponsors


Tan Tock Seng Hospital (51 trials)

AbbVie logo

AbbVie (8 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems